Our goal
To unite the frontiers of engineered biology + hardware to treat many of the complex and devastating brain disorders affecting individuals and communities worldwide.
Neurological and neuropsychiatric disorders have enormous social and economic impacts. In the UK, one in six people has at least one neurological condition, with a cost to the NHS of £4.4 billion per year. These disorders go far beyond issues with movement and motor skills; they include Alzheimer’s, epilepsy, addiction, and depression. Many of these are neural circuit-level disorders, or problems with the ‘wiring’ of the brain, but current technologies lack the requisite precision and most are highly invasive.
We're seeking to develop next-generation precision neurotechnologies that can interface with the human brain at the circuit level, with cell type specificity across distributed brain regions. Armed with a deeper understanding of the brain today than ever before, we can leverage advances in brain-computer interfaces, AI, computational power, and gene therapies to achieve more precise and effective treatments for brain disorders. This will unlock the full potential of neurotechnology, alleviate bottlenecks, and move closer to a world in which personalised brain health care is available to everyone.
Pillars
This programme is split into four pillars, each with its own distinct objectives.
Non-invasive Interfaces
Developing cutting-edge technologies to read and modulate brain activity through electrical and acoustic fields, without direct brain contact.
Remote Interfaces
Enhancing the interaction of external fields with the brain, either via biological modification of the brain or microscopic brain implants.
Biological Interfaces
Pioneering the use of engineered cells as 'living' interfaces to repair damaged neural pathways and develop innovative approaches for long-term, circuit-level brain interfacing.
Future Adoption
Exploring how neurotechnologies can be designed inclusively, recognising the importance of engaging clinicians and people with lived experiences of brain disorders for greater, more equitable adoption of future tech.
Explore the funded projects
We're funding 19 teams with expertise across a myriad of disciplines and a strong institutional mix, spanning academia, non-profit R&D organisations, and startups. This portfolio of teams cuts across four workstreams: non-invasive interfaces, remote interfaces, biological interfaces, and future adoption of novel neurotechnologies.
Meet the programme team
Our Programme Directors are supported by a core team that provides a blend of operational coordination and highly specialised technical expertise.
Jacques Carolan
Programme Director
Jacques is an applied physicist and neuroscientist. Prior to joining ARIA as a founding Programme Director, he was a Discovery Fellow at UCL and a Marie Skłodowska-Curie Fellow at MIT. Jacques’ work involves applying the principles of physics and engineering to create next-generation, scalable tools that aim to radically change our understanding of the brain and ultimately be used to repair it.
Chloe Whitehouse
Science + Technology Lead
Chloe is a neuroscientist and bioengineer with over a decade of experience building advanced in vitro models of the brain. She brings deep expertise in biomaterials, 3D bioprinting, microfluidics, and drug discovery, with a record of translating cutting-edge science into industry-leading platforms. She most recently led the 3D biofabrication platform for neuroscience at Merck Sharp & Dohme (MSD).
Gillian Koehl
Science + Technology Lead
Gillian, a bioengineer, is passionate about advancing health through neurotechnology. She brings expertise in neuromodulation product development and biomaterials from her time at Blackrock Neurotechnology and Imperial College London. Gillian is currently on maternity leave.
Featured insights
The UK’s answer to Darpa wants to rewire the human brain
WIRED
Jacques Carolan and Kathleen Fisher speak to Wired about ARIA’s ambitions to tackle everything from epilepsy to Alzheimer's.
Scalable Neural Interfaces
In Scalable Neural Interfaces, we are exploring how to advance highly targeted minimally-invasive neurotechnologies to understand and repair the brain.
Massively Scalable Neurotechnologies
This programme is centred on the challenges of scaling and addressing bottlenecks around accessibility.